Biogen Stock Price and Value Analysis

Should you buy Biogen stock? (NasdaqGS:BIIB). Let's see how it does in our automated value investing analysis system.

  • This company is very stable.
  • This company has fluctuating growth.
  • This company is making money at a modest rate.
  • This stock looks overpriced.
  • This company pays no dividend.

BIIB Free Cash Flow Trend

Based on historical returns, we believe that Biogen can grow its free cash at a rate of about 3%. That's positive!

Free Cash Flow trendline for BIIB
Free Cash Flow trendline for Biogen

Inside the BIIB Numbers

BIIB Price
(Biogen stock price per share)
[?] BIIB Fair Price
(based on intrinsic value)
[?] BIIB Safety Price (based on a variable margin of safety) $144.24
[?] PE Ratio versus Sector 10% higher than other Healthcare stocks
[?] PE Ratio versus Industry 57.8% higher than other Biotechnology stocks
[?] Cash Yield 5.77%
[?] Free Cash Flow Jitter 30%

Is Biogen Stock on Sale?

We believe that Biogen may be worth examining further. It's making money, which is a very positive sign. Is it on sale?

Biogen looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.

Should You Buy BIIB Stock?

Does Biogen have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.